Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Eptifibatide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 known ✓ | P05106 | 1/20 | 0.80 |
| ▸ | ITGA2B known ✓ | P08514 | 1/20 | 0.80 |
| ▸ | ITGAV | P06756 | 1/20 | 0.80 |
| ▸ | LDLR | P01130 | 6/20 | 0.56 |
| ▸ | PCSK9 | Q8NBP7 | 6/20 | 0.56 |
| ▸ | TSLP | Q969D9 | 10/20 | 0.55 |
| ▸ | MC4R | P32245 | 1/20 | 0.53 |
| ▸ | MC5R | P33032 | 1/20 | 0.53 |
| ▸ | MC3R | P41968 | 1/20 | 0.53 |
| ▸ | MC1R | Q01726 | 1/20 | 0.53 |
| ▸ | NECTIN4 | Q96NY8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eptifibatide SCHEMBL8284422 | 0.98 | ITGB3 (0.82) | ITGB3ITGAVITGA2BLDLRPCSK9 | |
| Eptifibatide SCHEMBL15781 | 0.98 | ITGB3 (0.82) | ITGB3ITGAVITGA2BLDLRPCSK9 | |
| Eptifibatide SCHEMBL29398425 | 0.98 | ITGB3 (0.82) | ITGB3ITGAVITGA2BLDLRPCSK9 | |
| Eptifibatide SCHEMBL571287 | 0.98 | ITGB3 (0.82) | ITGB3ITGAVITGA2BLDLRPCSK9 | |
| Eptifibatide SCHEMBL7107217 | 0.98 | ITGB3 (0.81) | ITGB3ITGAVITGA2BLDLRPCSK9 | |
| Eptifibatide SCHEMBL21753462 | 0.98 | ITGB3 (0.81) | ITGB3ITGAVITGA2BLDLRPCSK9 | |
| SCHEMBL24433365 | 0.97 | ITGB3 (0.81) | ITGB3ITGAVITGA2BLDLRPCSK9 | |
| SCHEMBL22193885 | 0.97 | ITGB3 (0.81) | ITGB3ITGAVITGA2BLDLRPCSK9 | |
| Eptifibatide SCHEMBL2830072 | 0.95 | ITGB3 (0.78) | ITGB3ITGAVITGA2BLDLRPCSK9 | |
| Eptifibatide SCHEMBL21753468 | 0.94 | ITGB3 (0.76) | ITGB3ITGAVITGA2BLDLRPCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119219735-A | Reduction-oxidation system method for preparing eptifibatide | 深圳翰宇药业股份有限公司 | 2024-12-31 | — | — | CN | claimed |
| EP-2145962-B1 | Process for the manufacture of eptifibatide | PEPTISYNTHA SA (BE) | 2016-11-16 | — | — | EP | claimed |
| WO-2013057736-A2 | PREPARATION OF EPTIFIBATIDE PEPTIDE | EMCURE PHARMACEUTICALS LIMITED (IN) | 2013-04-25 | — | — | WO | claimed |
| US-20110118437-A1 | Process for the Synthesis of Cyclic Heptapeptide | USV LIMITED (IN) | 2011-05-19 | — | — | US | claimed |
| EP-2145962-A2 | Process for the manufacture of eptifibatide | Solvay SA (BE) | 2010-01-20 | — | — | EP | claimed |
| EP-1904641-B1 | PROCESS FOR THE MANUFACTURE OF EPTIFIBATIDE | SOLVAY (BE) | 2009-09-16 | — | — | EP | claimed |
| EP-1773870-A2 | METHODS FOR THE PRODUCTION OF PEPTIDE HAVING A C-TERMINAL AMIDE | Novetide Ltd. (IL) | 2007-04-18 | — | — | EP | claimed |
| US-20060276626-A1 | Methods for the production of peptide derivatives | TEVA PHARMACEUTICALS USA, INC. | 2006-12-07 | — | — | US | claimed |
| WO-2006119388-A2 | METHODS FOR THE PRODUCTION OF PEPTIDE HAVING A C-TERMINAL AMIDE | NOVETIDE, LTD. (IL) | 2006-11-09 | — | — | WO | claimed |
| EP-1709065-A2 | A COUNTERION EXCHANGE PROCESS FOR PEPTIDES | Novetide Ltd. (IL) | 2006-10-11 | — | — | EP | claimed |
| US-20060148699-A1 | Counterion exchange process for peptides | TEVA PHARMACEUTICALS USA, INC. | 2006-07-06 | — | — | US | claimed |
| WO-2006041945-A2 | A COUNTERION EXCHANGE PROCESS FOR PEPTIDES | NOVETIDE, LTD. (IL) | 2006-04-20 | — | — | WO | claimed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | RECEPTIVE BIO INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12392768-B2 | Methods for determining blood gas or metabolic parameters | RADIOMETER MEDICAL APS (DK) | 2025-08-19 | — | — | US | disclosed |
| US-12228567-B2 | Colorimetric sensor kit for screening therapeutic agent for neurodegenerative disease, including amyloid shelled-gold nanoparticle, and method for screening therapeutic agent for neurodegenerative disease | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2025-02-18 | — | — | US | disclosed |
| WO-2006119388-A2 | METHODS FOR THE PRODUCTION OF PEPTIDE HAVING A C-TERMINAL AMIDE | NOVETIDE, LTD. (IL) | 2006-11-09 | — | — | WO | disclosed |
| EP-1709065-A2 | A COUNTERION EXCHANGE PROCESS FOR PEPTIDES | Novetide Ltd. (IL) | 2006-10-11 | — | — | EP | disclosed |
| US-20060148699-A1 | Counterion exchange process for peptides | TEVA PHARMACEUTICALS USA, INC. | 2006-07-06 | — | — | US | disclosed |
| WO-2006041945-A2 | A COUNTERION EXCHANGE PROCESS FOR PEPTIDES | NOVETIDE, LTD. (IL) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148699-A1 | Counterion exchange process for peptides | VIP, NPPA, SLC26A3 | ITGB3 3515/4885ITGA2B 4403/4885ITGAV 3286/4885 |
| US-20110118437-A1 | Process for the Synthesis of Cyclic Heptapeptide | PTMS, C9, VIP | ITGB3 3085/4885ITGA2B 3893/4885ITGAV 3822/4885 |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | CA4, FLT4, CAMK4 | ITGB3 403/4885ITGA2B 981/4885ITGAV 361/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | ITGB3 1125/4885ITGA2B 1286/4885ITGAV 1364/4885 |
| US-20060276626-A1 | Methods for the production of peptide derivatives | VIP, IAPP, PTMS | ITGB3 4019/4885ITGA2B 4596/4885ITGAV 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.